TEL: (019467) 74716
Compensation Scheme Executive Secretariat, Sellafield Limited
Sellafield, Seascale, Cumbria CA20 1PG

Annual Statement



The Compensation Scheme for Radiation Linked Diseases (CSRLD) is a joint initiative between the UK's nuclear-sector employers and their trade unions.  The scheme is designed to provide an alternative to legal action for past and present employees of participating employers who have been exposed to radiation during their work and who are subsequently diagnosed to be suffering from cancer or cataracts.  It has had a successful year and is continuing to process cases.

The scheme has been in existence since 1982 and the participating employers have expanded since its inception to include: Sellafield Ltd, Springfields Fuels Ltd, United Kingdom Atomic Energy Authority, URENCO UK Ltd, EDF Energy Nuclear Generation Ltd, Magnox Ltd, the Ministry of Defence, AWE plc, Babcock Marine (Devonport Royal Dockyard) Ltd, Babcock Marine (Rosyth Royal Dockyard) Ltd, Babcock Marine (Clyde) Ltd, GE Healthcare Ltd, Low Level Waste Repository (Drigg), Dounreay Site Restoration Limited and other related Specified Companies.

The nuclear-sector employers and the Nuclear Decommissioning Authority are fully supportive of the Compensation Scheme which provides nearly complete coverage of the UK nuclear industry employees.

The participating trade unions and staff associations are the Civil Nuclear Police Federation, the FDA, GMB, Prospect, UNITE (incl Union of Construction, Allied Trades and Technicians), UNISON and the Defence Police Federation.

Cases which can be considered under the scheme are assessed by the application of technical criteria jointly agreed between management and trade unions. The applied criteria are more generous to the claimant than those likely to be used for a legal action. The CSRLD contains further generosity in that it awards payments for cases with a causation probability of 20% or above. In a court case a claimant must prove a causation probability of 50% where an ‘all or nothing’ approach based on the balance of probabilities is applied.

In line with a commitment to ensure that the scheme reflects the latest scientific and technical knowledge, new schedules were implemented in 2009 based on the findings of the BEIR Vll and UNSCEAR reports of 2006. (Changes in science can result in increases or decreases in causation probability). At this time the reports of 2006 continue to present the best available basis for the Scheme’s assessment methodology. The Scheme’s Technical Working Party continues to maintain a watching brief on Technical developments.

Upon implementation of the revised Schedules in 2009, the Compensation Scheme carried out a review of all previous cancer cases using the new technical basis to arrive at an understanding of causation probability for those cases capable of being caused (or influenced) by radiation. (This review is referred to as a retrospection exercise) It then secured agreement from the funding bodies for the duty holder organisations to undertake, as appropriate, financial settlement proceedings. These proceedings are nearing completion. However this revised technical basis did not include cataracts. In 2011 the International Commission for Radiological Protection (ICRP) issued a statement on tissue reactions that recommended a reduction in the absorbed dose threshold for the induction of cataracts. To reflect the changes in the ICRP recommendations a revised cataract schedule was produced by the scheme and implemented in 2012. Following approval from the relevant duty holder organisations, a cataract retrospection exercise has been undertaken, successful cases identified and steps initiated to progress these claims to financial settlement.

Following on from a Scheme review and Technical revisions, Council agreement was reached in 2015 on the implementation of revised Scheme Governance arrangements and protocols in support of case progressing. As a result of the revised Data Protection Regulations the Scheme has been implementing updated data protection arrangements. The Scheme has also been reviewing its record retention arrangements.

The Scheme received 26 new claims during the 2018/19 financial year. One claim proved successful and is under negotiation. A further 11 compensation settlements reached completion, all of which were identified following the main retrospection exercise.

There have been 1660 cases considered/received since the Scheme began. 162 of these cases have resulted in successful claims. To date compensation payments amounting to £8.740m have been paid to claimants. The successful cases include 16 cases which were identified during the main retrospection exercise, plus 4 cases (identified to date) following the cataract retrospection exercise.

Information about CSRLD is available to interested parties via the internet. The scheme’s website ( has been upgraded this year to improve access by modern platforms such as Tablets & Smart phones. The website is designed primarily to provide relevant guidance to potential claimants (and others acting on their behalf) but also provides contact information for those seeking further information. Over the past year the site has continued to receive many regular visits, and has provided the means to initiate a number of claims.

For further information please contact:-

The Compensation Scheme Executive Secretariat

 Sellafield Ltd.


Cumbria CA20 1PG

Tel 019467 74716

June 2019


Each Compensation Scheme Management Board (CSMB) produces a progress report , examples from the NDA Sites and MoD/AWE Boards are attached below.

The updated Specified Companies summaries & schedules are also attached.